$Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection$
QR Code

QR Code

Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection

Background Tisagenlecleucel, an anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy, has demonstrated durable efficacy and a manageable safety profile in pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) in the ELIANA pivotal trial and rea...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Weijie Li, Keith J August, Erin M Hall, Dwight E Yin, Rakesh K Goyal, Atif A Ahmed, Grace S Mitchell, Shawn D St. Peter, Terrie G Flatt, Ibrahim A Ahmed, Richard J Hendrickson, G Doug Myers
Format:	article
Langue:	EN
Publié:	BMJ Publishing Group 2021
Sujets:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/ebd8b85ed1f64889854a9550a505497f
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Correction: Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection
Publié: (2021)

Refractory relapsing polychondritis: challenges and solutions
par: Kemta Lekpa F, et autres
Publié: (2018)

Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma
par: Mary H. Young, et autres
Publié: (2021)

Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
par: Gupta VA, et autres
Publié: (2013)

TREATMENT OF RELAPSED, REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
par: Ebru Pekgüç, et autres
Publié: (2021)

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
par: Nooka A, et autres
Publié: (2013)

Pharmacological dose ascorbic acid administration in relapsed refractory multiple myeloma patients
par: Ali Zahit Bolaman, et autres
Publié: (2021)

Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy
par: Sigmund AM, et autres
Publié: (2020)

IDH1-mutated relapsed or refractory AML: current challenges and future prospects
par: Megías-Vericat JE, et autres
Publié: (2019)

Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
par: Illidge T, et autres
Publié: (2012)

Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
par: Shansa Pranami E. Jayaweera, et autres
Publié: (2021)

Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine
par: Davis T, et autres
Publié: (2013)

Seriously sexy
par: Gallanti,Fabrizio
Publié: (2006)

Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
par: Karantanos T, et autres
Publié: (2017)

Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function
par: Li Y, et autres
Publié: (2017)

Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib
par: Harvey RD
Publié: (2014)

Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma
par: Chetan Rathi, et autres
Publié: (2021)

Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies
par: Yildiz H, et autres
Publié: (2021)

Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
par: Joseph NS, et autres
Publié: (2021)

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
par: Weiping Liu, et autres
Publié: (2021)

Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma
par: Edvan de Queiroz Crusoé, et autres
Publié: (2021)

Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis
par: Jia Li, et autres
Publié: (2021)

Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
par: Hagop M. Kantarjian, et autres
Publié: (2021)

Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL
par: Biping Deng, et autres
Publié: (2021)

Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey
par: Ayşe Hilal Eroğlu Küçükdiler, et autres
Publié: (2021)

Taking Religious Claims Seriously

Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations
par: Artem Gusak, et autres
Publié: (2021)

The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
par: Julio Delgado, et autres
Publié: (2021)

Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing
par: Fan Gao, et autres
Publié: (2021)

Sequential Transplantation of Haploidentical Stem Cell and Unrelated Cord Blood With Using ATG/PTCY Increases Survival of Relapsed/Refractory Hematologic Malignancies
par: Hua Li, et autres
Publié: (2021)

Gemtuzumab ozogamicin is efficacious in attaining complete remission in relapsed/refractory acute leukemia prior to hematopoietic cell transplant: A case series
par: Giancarlo Fatobene, et autres
Publié: (2021)

Endoscopic dissection of refractory pancreatic duct stricture via accessory pancreatic duct approach for concurrent treatment of anomalous pancreaticobiliary junction in aging patients
par: Wang T, et autres
Publié: (2019)

Transcriptome analysis of ABCB1, ABCG2 and the BCL2/BAX ratio in refractory and relapsed canine lymphomas under treatment and rescue protocol
par: Sirivisoot Sirintra, et autres
Publié: (2018)

Serious games: Theory in anthropology since the 1980s
par: Aleksandar Bošković
Publié: (2016)

Serious games: Theory in anthropology since the 1980s
par: Aleksandar Bošković
Publié: (2016)

Violence against nurses: A serious issue in Indonesia
par: Ramadhan Tosepu, et autres
Publié: (2021)

The effect of a serious game on aviation vocabulary acquisition
par: Nazmi Dinçer, et autres
Publié: (2021)

Insurance Fraud in Korea, Its Seriousness, and Policy Implications
par: Jeyong Jung, et autres
Publié: (2021)

Journey to zero serious bacterial prosthetic joint infection
par: Mette Walberg, et autres
Publié: (2021)

EFFECT OF INTRAVITREAL TRIAMCINOLONE ACETONIDE IN REFRACTORY DIABETIC MACULAR EDEMA
par: Ume Sughra, et autres
Publié: (2021)